Derek Wainwright to Neoplasms
This is a "connection" page, showing publications Derek Wainwright has written about Neoplasms.
Connection Strength
1.090
-
Quantification of IDO1 enzyme activity in normal and malignant tissues. Methods Enzymol. 2019; 629:235-256.
Score: 0.227
-
The Boosting Potential of Bacteria in Cancer Immunotherapy. Trends Mol Med. 2017 07; 23(7):580-582.
Score: 0.195
-
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res. 2015 Dec 15; 21(24):5427-33.
Score: 0.175
-
CD8+ T cells sustain antitumor response by mediating crosstalk between adenosine A2A receptor and glutathione/GPX4. J Clin Invest. 2024 Mar 05; 134(8).
Score: 0.078
-
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375.
Score: 0.064
-
NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021 01 06; 14(1):7.
Score: 0.063
-
Targeting CD73 to augment cancer immunotherapy. Curr Opin Pharmacol. 2020 08; 53:66-76.
Score: 0.061
-
Systematic Review of the Kynurenine Pathway and Psychoneurological Symptoms Among Adult Cancer Survivors. Biol Res Nurs. 2020 10; 22(4):472-484.
Score: 0.060
-
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. Front Immunol. 2020; 11:1185.
Score: 0.060
-
Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy. J Immunother Cancer. 2019 08 26; 7(1):223.
Score: 0.057
-
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer. J Immunother Cancer. 2017 09 19; 5(1):77.
Score: 0.050